Stage, Age, Comorbidity, and Direct Costs of Colon, Prostate, and Breast Cancer Care

Taplin, Stephen H.; Barlow, William; Urban, Nicole; Mandelson, Margaret T.; Timlin, Deborah; Ichikawa, Laura; Nefcy, Pauline

doi:10.1093/jnci/87.6.417

Cited by 321 publications

(218 citation statements)

References 0 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…Although nearly half of stage IV patients did not receive initial treatment, these patients were more likely to have multiple hospitalizations compared to stage III, which likely was a factor in driving up costs. These results contrast with Taplin et al 7 in that we observed increases in health-care utilization and costs among both regional and distant stages relative to local. As in our study, PCa-related costs were defined as the net costs between PCa cases and a group of age-matched controls.…”

Section: Discussioncontrasting

confidence: 99%

“…Several studies have been conducted that examine the effect of PCa stage on initial treatment costs with conflicting results. [7][8][9] The majority of costs related to PCa occur during the period of initial treatment. Both Taplin et al 7 and Penberthy et al 8 reported that initial PCa stage did not affect treatment costs whereas Penson et al 9 concluded that first-year costs do increase by stage particularly for patients treated with radical prostatectomy.…”

Section: Introductionmentioning

confidence: 99%

“…[7][8][9] The majority of costs related to PCa occur during the period of initial treatment. Both Taplin et al 7 and Penberthy et al 8 reported that initial PCa stage did not affect treatment costs whereas Penson et al 9 concluded that first-year costs do increase by stage particularly for patients treated with radical prostatectomy. The purpose of this study was to estimate first-year PCa costs and to examine the extent to which costs and utilization vary by initial stage.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

Roehrborn

Albertsen

Stokes

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13 091, prevention strategies have the potential to reduce health-care costs.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

Roehrborn

Albertsen

Stokes

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Furthermore, many of the studies identified only examine costs for patients diagnosed with early stage PCa. [6][7][8] A few older studies 9,10 have examined costs in phases of care beyond initial treatment and have stratified estimates by cancer stage. However, these studies consider costs over earlier periods (1990-1991 9 and 1973-1991 10 ), which may be less relevant today given the changes in approach to PCa diagnosis and treatment that have occurred.…”

Section: Introductionmentioning

confidence: 99%

Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data

Stokes¹,

Black²,

Benedict³

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Limited data are available concerning long-term prostate cancer (PCa)-related medical costs for use in assessing PCa prevention strategies. The aim of this study was to examine treatment, long-term survival, and long-term PCa-related costs by cancer stage. Costs in phases of care based on the natural history of PCa were also examined. Our data illustrate that initial care is characteristic of a rapid rate of cost accrual. This rate then decreases during continuing care. For terminal care, only stage IV resumes a rate of cost accrual similar to initial care. With average PCa-related costs of $18 168 observed over an average follow-up of 4 years, prevention strategies may result in a reduction in medical costs.

show abstract

“…There is no evidence that the SEER-Medicare data are not reflective of national enrollment patterns in FFS and HMOs. Previous research has found that expense patterns generated from SEER-Medicare and HMO data are roughly consistent (9)(10)(11); no studies, however, have systematically examined how cancer-specific and longitudinal patterns of resource and service use and overall expense differ between HMOs and Medicare. Building on the work of the Cancer Research Network [CRN (12)(13)(14)], the Burden of Cancer study (BURDEN) has developed a multisite, multipayer database to support analyses extending and complementing the linked SEER-Medicare data.…”

Section: Measuring the Medical Cost Of Cancermentioning

confidence: 99%

A Standardized Relative Resource Cost Model for Medical Care: Application to Cancer Control Programs

et al. 2013

View full text Add to dashboard Cite

Medicare data represent 75% of aged and permanently disabled Medicare beneficiaries enrolled in the fee-for-service (FFS) indemnity option, but the data omit 25% of beneficiaries enrolled in Medicare Advantage health maintenance organizations (HMOs). Little research has examined how longitudinal patterns of utilization differ between HMOs and FFS. The Burden of Cancer Study developed and implemented an algorithm to assign standardized relative costs to HMO and Medicare FFS data consistently across time and place. Medicare uses 15 payment systems to reimburse FFS providers for covered services. The standardized relative resource cost algorithm (SRRCA) adapts these various payment systems to utilization data. We describe the rationale for modifications to the Medicare payment systems and discuss the implications of these modifications. We applied the SRRCA to data from four HMO sites and the linked Surveillance, Epidemiology, and End Results-Medicare data. Some modifications to Medicare payment systems were required, because data elements needed to categorize utilization were missing from both data sources. For example, data were not available to create episodes for home health services received, so we assigned costs per visit based on visit type (nurse, therapist, and aide). For inpatient utilization, we modified Medicare's payment algorithm by changing it from a flat payment per diagnosis-related group to daily rates for diagnosis-related groups to differentiate shorter versus longer stays. The SRRCA can be used in multiple managed care plans and across multiple FFS delivery systems within the United States to create consistent relative cost data for economic analyses. Prior to international use of the SRRCA, data need to be standardized.

show abstract

Stage, Age, Comorbidity, and Direct Costs of Colon, Prostate, and Breast Cancer Care

Abstract: More needs to be done to explore the reasons and implications of age-related cost differences. Cost-effectiveness analyses of cancer control interventions that shift cancer stage distributions may need to consider both the age and comorbidity of the target populations.

Cited by 321 publications

References 0 publications

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data

A Standardized Relative Resource Cost Model for Medical Care: Application to Cancer Control Programs

Contact Info

Product

Resources

About